Non-ACE pathway-induced angiotensin II production

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3054-3059

  Uehara, Yoshinari ^a   Miura, Shin ichiro ^a,b   Yahiro, Eiji ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ACE; Angiotensin II; Angiotensin (1 12); Cardiovascular disease; Chymase; Elastase 2; Local renin angiotensin system

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; APROTININ; CAPTOPRIL; CATHEPSIN G; CHYMASE; CHYMASE INHIBITOR; CHYMOSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTASE; ELASTASE II; INTERLEUKIN 1BETA; KALLIKREIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; NAFAMSTAT; RENIN; SUNC 8257; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; HEART; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; ATHEROSCLEROSIS; CHYMASES; HUMANS; MYOCARDIUM; SERINE ENDOPEPTIDASES;

EID: 84878643154     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170012     Document Type: Article

References (86)

1. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Archives of internal medicine. 1984;144(10):1947-53. Epub 1984/10/01.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325(5):293-302. Epub 1991/08/01.
3. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension. 1987;9(6 Pt 2):III42-8. Epub 1987/06/01.
4. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. The American journal of cardiology. 1994;73(7):488-93. Epub 1994/03/01.
5. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension. 1986;8(7):553-9 issn: 0194-911x.
6. Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiological reviews. 2006;86(3):747-803. Epub 2006/07/04.
7. Gondo M, Maruta H, Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Japanese heart journal. 1989;30(2):219-29. Epub 1989/03/01.
8. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 1993;27(2):334-40. Epub 1993/02/01.
9. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265(36):22348-57.
10. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens. 1994;12(Suppl 9):S17-22.
11. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66(4):883-90.
12. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Japanese journal of pharmacology. 1993;62(2):207-10.
13. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 1998;32(3):514-20.
14. Nishimura H, Buikema H, Baltatu O, Ganten D, Urata H. Functional evidence for alternative ANG II-forming pathways in hamster cardiovascular system. Am J Physiol. 1998;275(4 Pt 2):H1307-12.
15. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999;33(6):1399-405.
16. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994;90(4):1669-78.
17. Paananen K, Kovanen PT. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules. J Biol Chem. 1994;269(3):2023-31 Issn: 0021-9258.
18. Banovac K, De Forteza R. The effect of mast cell chymase on extracellular matrix: studies in autoimmune thyroiditis and in cultured thyroid cells. International archives of allergy and immunology. 1992;99(1):141-9.
19. Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J Biol Chem. 1994;269(27):18134-40.
20. Vartio T, Seppa H, Vaheri A. Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J Biol Chem. 1981;256(1):471-7. Epub 1981/01/10.
21. Kofford MW, Schwartz LB, Schechter NM, Yager DR, Diegelmann RF, Graham MF. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem. 1997;272(11):7127-31.
22. Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866-74.
23. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-8.
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801-9.
25. Grafe M, Auch-Schwelk W, Zakrzewicz A, et al. Angiotensin IIinduced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res. 1997;81:804-11.
26. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun. 1996;226(3):862-8.
27. Hahn AW, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 1994;347:178-80.
28. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68(2):450-6.
29. Bell L, Luthringer DJ, Madri JA, Warren SL. Autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of protooncogene pp60c-src expression. J Clin Invest. 1992;89:315-20.
30. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990;137:7-12.
31. Kato H, Suzuki H, Tajima S, et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens. 1991;9:17-22.
32. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation-Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-23.
33. Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res. 1991;69:1293-300.
34. Chobanian AV. The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol. 1990;13(6 Suppl 7):VII43-8.
35. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992;20(4):473-7.
36. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest. 1993;91(4):1453-8.
37. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94(11):2756-67.
38. Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am J Physiol. 1996;271(3 Pt 2):H1065-71.
39. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997;412(1):86-90.
40. Uehara Y, Urata H, Sasaguri M, et al. Increased Chymase Activity in Internal Thoracic Artery of Patients with Hypercholesterolemia. Hypertension. 2000;35(1):55-60.
41. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 2002;55(4):870-6.
42. Takai S, Jin D, Nishimoto M, et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life sciences. 2001;69(15):1725-32. Epub 2001/10/23.
43. Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. Int J Cardiol. 1997;54 Suppl:S21-S35.
44. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1B induces coronary intimal lesions and vasospastic responses in pigs in vivo The role of platelet-derived growth factor. J Clin Invest. 1996;97:769-76.
45. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol. 1991;138:951-60.
46. Bonin PD, Fici GJ, Singh JP. Interleukin-1 promotes proliferation of vascular smooth muscle cells in coordination with PDGF or a monocyte-derived growth factor. Exp Cell Res. 1989;181:475-82.
47. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med. 1991;174(4):821-5.
48. Bydlowski SP. Mast cell:Its mediators and effects on arterial wall metabolism. GenPharmacol. 1986;17:625-31.
49. Lees M, Taylor DJ, Woolley DE. Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Eur J Biochem. 1994;223(1):171-7 Issn: 0014-2956.
50. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe(88)-Gln(89) and Phe(91)-Glu(92) bonds of the catalytic domain. J Biol Chem. 1997;272(41):25628-35.
51. Takai S, Jin D, Ohzu M, Tanaka K, Miyazaki M. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. Journal of pharmacological sciences. 2009;110(4):459-65. Epub 2009/08/05.
52. Rafiq K, Sherajee SJ, Fan YY, et al. Blood glucose level and survival in streptozotocin-treated human chymase transgenic mice. The Chinese journal of physiology. 2011;54(1):30-5. Epub 2011/07/27.
53. Maeda Y, Inoguchi T, Takei R, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. American journal of physiology Renal physiology. 2010;299(6):F1328-38. Epub 2010/10/01.
54. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacological reviews. 2000;52(1):11-34. Epub 2000/03/04.
55. Sadoshima J, Izumo S. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73(3):413-23. Epub 1993/09/01.
56. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91(4):1269-81.
57. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annual review of physiology. 1992;54:227-41. Epub 1992/01/01.
58. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissuespecific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69(2):475-82. Epub 1991/08/01.
59. Meggs LG, Coupet J, Huang H, et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res. 1993;72(6):1149-62. Epub 1993/06/01.
60. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. Journal of molecular and cellular cardiology. 1993;25(11):1369-80. Epub 1993/11/01.
61. Ihara M, Urata H, Shirai K, et al. High cardiac angiotensin-IIforming activity in infarcted and non-infarcted human myocardium. Cardiology. 2000;94(4):247-53.
62. Takai S, Jin D, Sakaguchi M, Kirimura K, Miyazaki M. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Japanese journal of pharmacology. 2001;86(1):124-6. Epub 2001/06/30.
63. Hoshino F, Urata H, Inoue Y, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. Journal of cardiovascular pharmacology. 2003;41 Suppl 1:S11-8. Epub 2003/04/12.
64. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107(20):2555-8. Epub 2003/05/14.
65. Koga T, Urata H, Inoue Y, et al. Human chymase expression in a mice induces mild hypertension with left ventricular hypertrophy. Hypertens Res. 2003;26(9):759-68.
66. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun. 2006;350(4):1026-31. Epub 2006/10/19.
67. Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension. 2010;55(2):445-52. Epub 2009/12/23.
68. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res. 2009;82(1):40-50. Epub 2009/01/17.
69. Prosser HC, Richards AM, Forster ME, Pemberton CJ. Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system. Peptides. 2010;31(8):1540-5. Epub 2010/05/25.
70. Arakawa H, Chitravanshi VC, Sapru HN. The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1-12) and angiotensin II. American journal of physiology Heart and circulatory physiology. 2011;300(3):H951-60. Epub 2010/12/28.
71. Arnold AC, Isa K, Shaltout HA, et al. Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. American journal of physiology Heart and circulatory physiology. 2010;299(3):H763-71. Epub 2010/06/22.
72. Chitravanshi VC, Sapru HN. Cardiovascular responses elicited by a new endogenous angiotensin in the nucleus tractus solitarius of the rat. American journal of physiology Heart and circulatory physiology. 2011;300(1):H230-40. Epub 2010/11/16.
73. Isa K, Garcia-Espinosa MA, Arnold AC, et al. Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. American journal of physiology Regulatory, integrative and comparative physiology. 2009;297(1):R111-5. Epub 2009/05/01.
74. Jessup JA, Trask AJ, Chappell MC, et al. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. American journal of physiology Heart and circulatory physiology. 2008;294(6):H2614-8. Epub 2008/04/15.
75. Ferrario CM, Varagic J, Habibi J, et al. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. American journal of physiology Heart and circulatory physiology. 2009;296(4):H1184-92. Epub 2009/02/17.
76. Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM. Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PloS one. 2011;6(1):e15759. Epub 2011/01/21.
77. Bujak-Gizycka B, Olszanecki R, Suski M, Madek J, Stachowicz A, Korbut R. Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2010;61(6):679-82. Epub 2011/01/13.
78. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. Journal of molecular medicine. 2008;86(6):663-71. Epub 2008/04/26.
79. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PloS one. 2011;6(12):e28501. Epub 2011/12/20.
80. Komatsu Y, Kida N, Nozaki N, et al. Effects of proangiotensin-12 infused continuously over 14 days in conscious rats. European journal of pharmacology. 2012;683(1-3):186-9. Epub 2012/03/15.
81. Nagata S, Kato J, Kuwasako K, Asami M, Kitamura K. Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system. Hypertens Res. 2012;35(2):234-8. Epub 2011/10/14.
82. McDonald JE, Padmanabhan N, Petrie MC, Hillier C, Connell JM, McMurray JJ. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. Circulation. 2001;104(15):1805-8. Epub 2001/10/10.
83. Richard V, Hurel-Merle S, Scalbert E, et al. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation. 2001;104(7):750-2. Epub 2001/08/15.
84. Becari C, Sivieri DO, Jr., Santos CF, Moyses MK, Oliveira EB, Salgado MC. Role of elastase-2 as an angiotensin II-forming enzyme in rat carotid artery. Journal of cardiovascular pharmacology. 2005;46(4):498-504. Epub 2005/09/15.
85. Becari C, Pereira HJ, Sivieri DO, Mesquita O, Oliveira EB, Salgado MCO. Angiotensin (1-12) Metabolism in Cardiac Perfusate of Wistar and Spontaneously Hypertensive Rats. Hypertension. 2010;56(5):E131-E.
86. Becari C, Teixeira FR, Oliveira EB, Salgado MC. Angiotensinconverting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme. American journal of physiology Heart and circulatory physiology. 2011;301(2):H565-70. Epub 2011/05/24.